Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Register entry · Comment-period correspondents

Zdenka Ximenes

Comment-period correspondent, pharmacovigilance. Academic nephrology unit

Document identifier
CEI-RG-141
Series
Register entry
Version
1.0
Published
15 Jan 2025
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Register entry

§1.1Register entry

Name
Zdenka Ximenes
Credentials
MPharm, MRPharmS
Role
Comment-period correspondent, pharmacovigilance
Body
Comment-period correspondents
Affiliation
Academic nephrology unit
Registered since
2025
Specialism
pharmacovigilance

§1.2Declared interests

Declared interests are published in full for every register entry. A declaration is not a disqualification, and the Institute has never given a submission or a review less weight on that ground. The materiality threshold and the recusal rules are set out in the conflicts-of-interest policy, which was settled through public consultation.

§1.3Attribution

Comment-period correspondents are listed in this register having consented at the point of submission. The Institute publishes no submission from a person who did not consent to be named.

Compound Evidence Institute · CEI-RG-141 · https://compoundevidence.com/people/zdenka-ximenes/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.